Premium
Iron Oxide Nanotubes for Magnetically Guided Delivery and pH‐Activated Release of Insoluble Anticancer Drugs
Author(s) -
Yue ZhanGuo,
Wei Wei,
You ZuoXiang,
Yang QinZheng,
Yue Hua,
Su ZhiGuo,
Ma GuangHui
Publication year - 2011
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.201100510
Subject(s) - materials science , nanotechnology , iron oxide nanoparticles , drug delivery , nanoparticle , iron oxide , paclitaxel , drug , targeted drug delivery , nanorod , peg ratio , chemical engineering , pharmacology , cancer , medicine , finance , economics , engineering , metallurgy
Low solubility in water is an intrinsic property of many drugs, which hinders the clinical use of those active ingredients. To break this bottleneck, we attempt to develop an iron oxide nanoparticle‐based multifunctional system. Firstly, we perform PEG coating and compare the feasibility of spherical and rod‐like iron oxide nanoparticles in a view of carcinoma cellular uptake; rod‐like nanoparticles attracted our interest since they could be quickly and massively internalized. For paclitaxel (PTX) loading, we next transform the nanorods into a tube structure by a hydrothermal method. The results show that drug crystals can be successfully loaded in the inner voids of these nanotubes (PMNTs) by controlling the crystallization process of PTX. The acquired nanocomplexes not only escape phagocytosis of macrophage cells by a PEG stealth effect, but also exhibit an increased cellular uptake with magnetic field exposure. In addition, this iron oxide‐based drug carrier possesses a low pH‐activated release profile, which would accelerate drug release in the carcinoma cells and minimize non‐specific drug release. Owing to these advantages, PMNTs promote the anticancer efficacy of PTX and clearly exhibit promising potential for using as high‐efficiency insoluble drug delivery system in clinical applications.